Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population
Open Access
- 13 April 1998
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 158 (7) , 777-781
- https://doi.org/10.1001/archinte.158.7.777
Abstract
CARRIER SCREENING for Tay-Sachs disease in the Ashkenazi Jewish population has been the paradigm for the development of heterozygote detection programs. Screening for Tay-Sachs disease started in the early 1970s, and to date more than 1 million individuals have been tested. The success of this program has been well documented, and it is highlighted by the reduced incidence of the disorder in the Ashkenazi Jewish population.1This publication has 11 references indexed in Scilit:
- The cost of treating Gaucher diseaseNature Medicine, 1996
- Canavan disease: From spongy degeneration to molecular analysisThe Journal of Pediatrics, 1995
- Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screeningBMJ, 1995
- Acceptability of carrier screening for cystic fibrosis during pregnancy in a German populationHuman Genetics, 1994
- The Ashkenazi Jewish Fanconi anemia mutation: Incidence among patients and carrier frequency in the at-risk populationHuman Mutation, 1994
- Gaucher disease mutations in non‐Jewish patientsBritish Journal of Haematology, 1993
- Efficient 12-mutation testing in the CFTR gene: a general model for complex mutation analysisHuman Molecular Genetics, 1993
- Screening for Carriers of Cystic Fibrosis among Pregnant Women: A Pilot StudyEuropean Journal of Human Genetics, 1993
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989
- PRENATAL SCREENING FOR CYSTIC FIBROSISPublished by Elsevier ,1982